Literature DB >> 28041966

Different roles of retinal dopamine in albino Guinea pig myopia.

Junfeng Mao1, Shuangzhen Liu2.   

Abstract

PURPOSE: To investigate whether the different role of ocular dopamine was involved in the myopic development between spontaneous myopia (SM) and form deprivation myopia (FDM) in albino guinea pigs.
METHODS: 55 myopic animals were randomly divided into SM, Levodapa (L-DOPA), L-DOPA+carbidopa and vehicle. 70 non-myopic animals were randomly divided into normal control, FDM, L-DOPA+FDM, L-DOPA+carbidopa+FDM and vehicle. Once per day, for 14days, L-DOPA (10mg/kg) was injected intraperitoneally, and carbidopa (1μg) was injected at the same time into the peribulbar space of the right eye. Refractive parameters and dopamine content in neural retina and RPE/choroid complex were measured.
RESULTS: In SM animals, high myopia was formed at 5 week of ages. L-DOPA treatment could reduce its myopic degree, and inhibit the increase of axial length and vitreous chamber depth with the increase of retinal dopamine in both eyes. Administration of carbidopa could prevent the increase of retinal dopamine induced by L-DOPA, but no influenced on its refractive state in the injected eyes. In non-SM animals, intraperitoneal L-DOPA could inhibit FDM, accompanied by the increase of retinal dopamine. Carbidopa treatment diminished the inhibition of FDM and prevented the increase in retinal dopamine by L-Dopa. Retinal dopamine was highly correlated with ocular refraction in FDM, but not in SM. There was no significant difference in dopamine content of RPE/choroid complex among all groups.
CONCLUSIONS: The role of retinal dopamine was different between SM and FDM in albino guinea pigs. Although systemic L-DOPA could inhibit the development of SM and FDM, retinal dopamine was only involved in the L-DOPA inhibition on FDM, but not on SM.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Albino; Dopamine; Form deprivation myopia; Levodapa; Spontaneous myopia

Mesh:

Substances:

Year:  2016        PMID: 28041966     DOI: 10.1016/j.neulet.2016.12.061

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

Review 1.  IMI - Report on Experimental Models of Emmetropization and Myopia.

Authors:  David Troilo; Earl L Smith; Debora L Nickla; Regan Ashby; Andrei V Tkatchenko; Lisa A Ostrin; Timothy J Gawne; Machelle T Pardue; Jody A Summers; Chea-Su Kee; Falk Schroedl; Siegfried Wahl; Lyndon Jones
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-02-28       Impact factor: 4.799

2.  Initiation of L-DOPA Treatment After Detection of Diabetes-Induced Retinal Dysfunction Reverses Retinopathy and Provides Neuroprotection in Rats.

Authors:  Kyle Chesler; Cara Motz; Harrison Vo; Amber Douglass; Rachael S Allen; Andrew J Feola; Machelle T Pardue
Journal:  Transl Vis Sci Technol       Date:  2021-04-01       Impact factor: 3.283

Review 3.  Update in myopia and treatment strategy of atropine use in myopia control.

Authors:  Pei-Chang Wu; Meng-Ni Chuang; Jessy Choi; Huan Chen; Grace Wu; Kyoko Ohno-Matsui; Jost B Jonas; Chui Ming Gemmy Cheung
Journal:  Eye (Lond)       Date:  2018-06-11       Impact factor: 3.775

4.  Effectiveness and safety of topical levodopa in a chick model of myopia.

Authors:  Kate Thomson; Cindy Karouta; Ian Morgan; Tamsin Kelly; Regan Ashby
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

5.  Form-Deprivation and Lens-Induced Myopia Are Similarly Affected by Pharmacological Manipulation of the Dopaminergic System in Chicks.

Authors:  Kate Thomson; Cindy Karouta; Regan Ashby
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-10-01       Impact factor: 4.799

6.  Retinal Dopamine D2 Receptors Participate in the Development of Myopia in Mice.

Authors:  Furong Huang; Ziheng Shu; Qin Huang; Kaijie Chen; Wenjun Yan; Wenjing Wu; Jinglei Yang; Qiongsi Wang; Fengjiao Wang; Chunlan Zhang; Jia Qu; Xiangtian Zhou
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-01-03       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.